Inherited thrombocytopenias (IT) are a group of hereditary disorders characterized by a reduced platelet count sometimes associated with abnormal platelet function, which can lead to bleeding but also to syndromic manifestations and predispositions to other disorders.
Defective Step of Thrombopoiesis | Affected Gene | Disorder | Pathogenic Mechanism (Reference) | Additional Features (e.g., Syndromic Manifestations, Predisposition) |
---|---|---|---|---|
Defective megakaryocyte maturation | ANKRD26 | ANKRD26-related thrombocytopenia | Loss of ANKRD26 silencing during the last phases of megakaryocytopoiesis causes ERK1/2 phosphorylation that interferes with megakaryocyte maturation [13] | Predisposition to hematological malignancies |
ETV6 | ETV6-related thrombocytopenia | ETV6 is a transcriptional repressor that promotes the late phases of megakaryopoiesis. Mutations in ETV6 cause defective megakaryocyte maturation and impaired proplatelet formation [14] | Predisposition to hematological malignancies | |
FLI1 | FLI1-related thrombocytopenia | FLI1 is a transcription factor regulating many genes associated with megakaryocyte development. Therefore, FLI1 mutations promote defective megakaryocyte maturation [15] | Not reported | |
FLI1 deletion | Paris-Trousseau syndrome/Jacobsen syndrome | Abnormalities of heart and face, intellectual disabilities | ||
FYB | FYB-related thrombocytopenia | ADAP is a protein involved in the remodeling of cytoskeleton. Mutations in ADAP cause defective maturation of megakaryocytes and clearance of platelets [16] | Mild iron deficiency anemia | |
GATA1 | GATA1-relate disease | GATA1 is a transcription factor regulating many genes associated with megakaryocyte development therefore GATA1 defects cause alterations of megakaryocyte maturation [17] | Dyserythropoietic anemia, beta-thalassemia, congenital erythropoietic porphyria, splenomegaly | |
GFI1B | GFI1B-related thrombocytopenia | GFI1B is a transcription factor involved in homeostasis of hematopoietic stem cells and development of megakaryocytes therefore GFI1B defects cause alterations of megakaryocyte maturation [18] | Mild myelofibrosis | |
HOXA11 | Amegakaryocytic thrombocytopenia with radio-ulnar synostosis | HOXA11 is a transcription factor involved in the regulation of early hematopoiesis, its defect causes reduced number of megakaryocytes [19] | Bilateral radioulnar synostosis, severe bone marrow failure culminating in aplastic anemia in majority of cases, cardiac and renal malformations, hearing loss, clinodactyly, skeletal abnormalities, pancytopenia |
|
MECOM | MECOM is a transcription factor involved in the regulation of early hematopoiesis, its defect causes reduced number of megakaryocytes [20] | |||
IKZF5 | IKZF5-related thrombocytopenia | IKZF5 is a previously unknown transcriptional regulator of megakaryopoiesis [21] |
Not reported | |
MPL | Congenital amegakaryocytic thrombocytopenia | MPL is the receptor for thrombopoietin. MPL defects cause impaired thrombopoietin binding and thus impaired megakaryocyte maturation [22] | Acquired bone marrow aplasia | |
NBEAL2 | Gray platelet syndrome | Mutations in NBEAL2 cause impaired megakaryocyte maturation however its role in megakaryocytopoiesis is not clear [23] | Myelofibrosis, immune dysregulation (autoimmune diseases, positive autoantibodies, reduced leukocyte counts), proinflammatory profile | |
RBM8A | Thrombocytopenia-absent radius | RBM8A is a protein of the exon-junction complex involved in RNA processing. It has been hypothesized that RBM8A defects cause wrong mRNA processing of unknown components of the TPO-MPL pathway impairing megakaryocyte maturation [24] | Bilateral radial aplasia, anemia, skeletal, urogenital, kidney, heart defects | |
RUNX1 | Familial platelet disorder with predisposition to hematological malignancies | RUNX1 is a transcription factor regulating many genes associated with megakaryocyte development therefore RUNX1 mutations promote defective megakaryocyte maturation [25] | Predisposition to hematological malignancies | |
THPO | THPO-related disease | THPO is the gene for thrombopoietin, essential for hematopoietic stem cell survival and megakaryocyte maturation [26] | Bone marrow aplasia | |
Defective platelet production/increased clearance | ACTB | Baraitser–Winter syndrome 1 with macrothrombocytopenia | Mutations in β-cytoplasmic actin inhibit the final stages of platelet maturation by compromising microtubule organization [27] | Microcephaly, facial anomalies, mild intellectual disability, developmental delay |
ACTN1 | ACTN1-related thrombocytopenia | ACTN-1 is involved in cytoskeletal remodeling, defects in ACTN-1 cause defective proplatelet formation [28] | Not reported | |
ARPC1B | Platelet abnormalities with eosinophilia and immune-mediated inflammatory disease | The actin-related protein 2/3 complex (Arp2/3) is a regulator of the actin cytoskeleton and its mutation causes impaired proplatelet formation [29] | Immunodeficiency, systemic inflammation, vasculitis, inflammatory colitis, eosinophilia, eczema, lymphadenomegaly, hepato-splenomegaly, growth failure | |
CYCS | CYCS-related thrombocytopenia | CYCS is a mitochondrial protein with a role in respiration and apoptosis. Mutations in CYCS cause ectopic premature proplatelet formation with an unknown mechanism [30] | Not reported | |
DIAPH1 | DIAPH1-related thrombocytopenia | DIAPH1 is involved in cytoskeletal remodeling, defects in DIAPH1 cause defective proplatelet formation [31] | Hearing loss | |
FLNA | FLNA-related thrombocytopenia | Filamin A is involved in cytoskeletal remodeling, defects in FLNA cause defective proplatelet formation [32] | Periventricular nodular heterotopia and otopalatodigital syndrome spectrum of disorders | |
GP1BA, GP1BB, GP9 (loss of function) |
Bernard–Soulier syndrome monoallelic | The intracellular portion of the GPIb/IX/V complex links the receptor to the cytoskeleton. Disruption of this link causes impaired proplatelet formation [33] | Not reported | |
Bernard–Soulier syndrome biallelic | ||||
GP1BA (gain of function) |
Platelet-type von Willebrand disease | The extracellular portion of the GPIb/IX/V complex binds VWF. Constitutive binding of VWF to its receptor triggers the Src kinases pathway causing impaired proplatelet formation, ectopic platelet production and increased platelet clearance [34] | Not reported | |
ITGA2B, ITGB3 | ITGA2B/ITGB3-related thrombocytopenia | Constitutive activation of αIIbβ3 causes cytoskeletal perturbation leading to impaired proplatelet formation [35,36] | Not reported | |
KDSR | Thrombocytopenia and erythrokeraderma | KDSR is an essential enzyme for de novo sphingolipid synthesis, this suggests an important role for sphingolipids as regulators of cytoskeletal organization during megakaryopoiesis and proplatelet formation [37] | Dermatologic involvement ranging from hyperkeratosis/ erythema to ichthyosis. One family with no or very mild skin lesions but associated anemia has been reported |
|
MYH9 | MYH9-related disorder | MYH9 regulates cytoskeleton remodeling and mediates signal transduction pathways involved in proplatelet formation. Abnormalities of MYH9 cause hyperactivation of the Rho/ROCK pathway causing ectopic platelet formation [38] | Kidney disease, cataract, deafness, elevated liver enzymes | |
MPIG6B | Thrombocytopenia, anemia and myelofibrosis | G6b-B is a transmembrane receptor with an ITIM motif with a not well defined role in proplatelet formation [39] | Microcitic anemia, myelofibrosis, leukocytosis may be present |
|
PRKACG | PRKACG-related thrombocytopenia | PKA activates many proteins involved in megakaryocyte and platelet function, among them FLNa and GPIbβ therefore its dysfunction causes impaired proplatelet formation [40] | Not reported | |
STIM1 | Stormorken syndrome | STIM1 mutations cause a constitutively active store operated Ca2+ release-activated Ca2+ (CRAC) channel which triggers Ca2+ entry with consequent increased clearance of activated platelets [41] | Tubular myopathy and congenital myosis. Severe immune dysfunction | |
TRPM7 | TRPM7-related thrombocytopenia | Defects of the Mg2+ channel TRPM7, a regulator of embryonic development and cell survival, cause cytoskeletal alterations resulting in impaired proplatelet formation [42] | Atrial fibrillation | |
TPM4 | TPM4-related thrombocytopenia | Tropomyosin 4 is an actin cytoskeletal regulator. Insufficient TPM4 expression in human and mouse megakaryocytes resulted in a defect in the terminal stages of platelet production [43] |
Not reported | |
TUBB1 | TUBB1-related thrombocytopenia | Tubulin beta1 is a major component of microtubules therefore defects in TUBB1 cause impaired proplatelet formation [44] | Not reported | |
WAS | Wiskott–Aldrich syndrome | The WASP protein is a regulator of the actin cytoskeleton and its defect causes ectopic platelet formation and increased platelet clearance [45] | Immunodeficiency, hematopoietic malignancies, eczema, autoimmune hemolytic anemia. |
|
X-linked thrombocytopenia | Not reported | |||
Other/unknown pathogenic mechanism | ABCG5, ABCG8 | Thrombocytopenia associated with sitosterolemia | ABCG5 and ABCG8 regulate plant sterol and cholesterol absorption. It is supposed that sterol-enriched platelets are more rapidly cleared [46] | Xanthomas and pre-mature coronary atherosclerosis due to hypercholesterolemia |
CDC42 | Takenouchi-Kosaki syndrome with macrothrombocytopenia |
CDC42 is a critical molecule in various biological processes including the cell cycle, cell division, and the formation of the actin cytoskeleton [47] | Defective growth and psychomotor development, intellectual disability, facial abnormalities, brain malformation, muscle tone abnormalities, immunodeficiency, eczema, hearing/visual disability, lymphedema, cardiac, genitourinary, and/or skeletal malformations |
|
GNE | GNE-related thrombocytopenia | GNE encodes an enzyme involved in the sialic acid biosynthesis pathway and it is known that thrombocytopenia is associated with increased platelet desialylation [48] | Some patients presented myopathy with rimmed vacuoles with onset in early adulthood |
|
SLNF14 | SLNF14-related thrombocytopenia | SLNF14 is an endoribonuclease and its role in the generation of thrombocytopenia is unknown [49] | Not reported | |
SRC | SRC-related thrombocytopenia | Src-family kinase regulates multiple signaling pathways, its role in the generation of thrombocytopenia is unknown [50] | Myelofibrosis, bone pathologies, bone marrow dysplasia, splenomegaly, congenital facial dysmorphism |
|
PTPRJ | PTPRJ-related thrombocytopenia | PTPRJ is a protein tyrosine phosphatase expressed abundantly in platelets and megakaryocytes, its role in the generation of thrombocytopenia is unknown [51] | None |
Disease | Inheritance | Gene | Bleeding Diathesis |
---|---|---|---|
Arthrogryposis, renal dysfunction and cholestasis | AR | VPS33B VIPAS39 |
Severe |
CalDAG-GEFI related platelet disorder | AR | RASGRP2 | Moderate-severe |
Cediak-Higashi Syndrome | AR | CHS1 | Moderate-severe |
Combined alpha-delta granule deficiency | AR/AD | Unknown | Mild-moderate |
COX-1 deficiency | AR/AD | PTGSA | Moderate-severe |
Delta granule deficiency | AR/AD | Unknown | Mild-moderate |
Glanzmann thrombasthenia | AR | ITGA2B, ITGB3 | Moderate-severe |
Glycoprotein IV (GPIV) deficiency | AR | GP4 | Mild |
Glycoprotein VI (GPVI) deficiency | AR | GP6 | Mild |
Gs platelet defect | AD (if paternally inherited) | GNAS | Mild |
Hermansky–Pudlak syndrome | AR | HPS1, ADTB3A, HPS3, HPS4, HPS5, HPS6, DTNBP1, BLOC1S3, AP3D1, BLOC1S6 | Moderate-severe |
Leukocyte adhesion deficiency, type III | AR | FERMT3 | Moderate-severe |
P2Y12 deficiency | AR | P2RY12 | Moderate-severe |
Phospholipase A2 (cPLA2) deficiency | not determined | PLA2G4A | Moderate-severe |
PKCδ deficiency | AR | PRKCD | Absent |
Primary secretion defect | AR/AD | Unknown | Mild-moderate |
Quebec platelet disorder | AD | PLAU | Moderate-severe |
Scott syndrome | AR | TMEM16F | Mild-moderate |
Thromboxane A2 receptor defect | AD | TBXA2R | Mild |
Tx synthase deficiency | AD/AR | TBXAS1 | Moderate |
Form | Disease | Inheritance | Degree of Thrombocytopenia | Key Laboratory Features | References |
---|---|---|---|---|---|
Syndromic | Amegakaryocytic thrombocytopenia with radio-ulnar synostosis (ATRUS) | AD | severe | Normal platelet size and morphology | [19,20] |
Baraitser–Winter syndrome 1 with macrothrombocytopenia | AD | absent | Macrothrombocytopenia; leukocytosis with eosinophilia, leukopenia | [27] | |
FLNA-related thrombocytopenia | XL | moderate | Macrothrombocytopenia; impaired platelet aggregation GPVI-triggered; heterogeneous α-granules, occasionally giant; abnormal distribution of FLNa | [32] | |
GATA-1-related disease | XL | severe | Macrothrombocytopenia; reduced platelet aggregation by collagen and ristocetin; reduced α-granule content and release | [17] | |
GNE-related thrombocytopenia | AR | from mild to severe | Macrothrombocytopenia | [48] | |
Gray platelet syndrome | AR | moderate/severe | Macrothrombocytopenia; grey or pale platelets; dyserytropoiesis; absence of α-granules; defective TRAP-induced platelet aggregation | [23] | |
Paris-Trousseau thrombocytopenia, Jacobsen syndrome | AD | severe | Macrothrombocytopenia; defective platelet aggregation by thrombin; giant α-granules | [15] | |
Platelet abnormalities with eosinophilia and immune-mediated inflammatory disease | AR | moderate | Small platelets; eosinophilia; reduced platelet spreading; decreased platelet dense granules | [29] | |
PTPRJ-related thrombocytopenia | AR | moderate/severe | Microthrombocytopenia; impaired activation by the GPVI-specific agonist convulxin and the thrombin receptor-activating peptide but normal response to ADP | [51] | |
SRC-related thrombocytopenia | AD | moderate/severe | Platelets deficient in granules and rich in vacuoles | [50] | |
Stormorken syndrome | AD | moderate/severe | Howell-Jolly bodies in red blood cells; enhanced annexin V binding, defective GPIIb/IIIa activation (PAC-1) | [41] | |
Takenouchi-Kosaki syndrome with macrothrombocytopenia |
AD | absent | Macrothrombocytopenia, abnormal platelet spreading and filopodia formation | [47] | |
Thrombocytopenia-absent radius syndrome (TAR) | AR | severe | Normal platelet size and morphology, thrombocytopenia | [24] | |
Thrombocytopenia and erythrokeraderma | AR | moderate | Thrombocytopenia and presence of 3-keto-dihydrosphingosine in plasma | [37] | |
Thrombocytopenia, anemia and myelofibrosis | AR | mild/moderate | Macrothrombocytopenia, anemia | [39] | |
Wiskott–Aldrich syndrome | XL | severe | Microthrombocytopenia; Reduced α/δ granules release | [45] | |
X-linked thrombocytopenia | XL | mild/moderate | Microthrombocytopenia; Reduced α/δ granules release | [45] | |
Non-syndromic | ACTN1-related thrombocytopenia | AD | mild | Macrothrombocytopenia | [28] |
Bernard Soulier syndrome monoallelic biallelic |
AD AR |
mild moderate/severe |
Macrothrombocytopenia; lack of platelet agglutination to ristocetin with normal aggregation to other agonists; severe reduction or complete lack of GPIb/IX/V | [33] | |
CYCS-related thrombocytopenia | AD | mild | Normal platelet size and morphology | [30] | |
FLI1-related thrombocytopenia | AD/AR | moderate | Reduced platelet aggregation in response to collagen and PAR-1 agonists; δ-granule deficiency | [15] | |
FYB-related thrombocytopenia | AR | moderate/severe | Microthrombocytopenia; increased expression of P-selectin and PAC-1 by resting platelets but impaired upon stimulation with ADP | [16] | |
GFI1b-related thrombocytopenia | AD/AR | mild/moderate | Macrothrombocytopenia; dyserytropoiesis; reduced α-granule content and release; diminished expression of GPIbα, red cell anisocytosis | [18] | |
IKZF5-related thrombocytopenia | AD | absent | Thrombocytopenia; deficiency of platelet alpha granules. | [21] | |
ITGA2B/ITGB3-related thrombocytopenia | AD | mild/moderate | Macrothrombocytopenia; reduced GPIIb/IIIa; defective GPIIb/IIIa activation (PAC-1) | [35,36,54] | |
PT-VWD | AD | mild/moderate | Macrothrombocytopenia; increased response to ristocetin and decreased VWF-ristocetin cofactor activity (VWF:RCo) Mixing tests discriminate the plasmatic (VWD type2B) from platelet (PT-VWD) origin of hyperreactivity to ristocetin | [36,76,77] | |
PRKACG-related thrombocytopenia | AR | severe | Macrothrombocytopenia; defective platelet αIIbβ3 activation and P-selectin exposure in response to TRAP6; defective Ca2+ mobilization in response to thrombin | [40] | |
THPO-related thrombocytopenia | AD | mild | Normal or slightly increased platelet size | [26] | |
TRPM7-related thrombocytopenia | AD | mild/moderate | Macrothrombocytopenia; aberrant distribution of granules | [42] | |
Tropomyosin 4 (TPM)-related thrombocytopenia | AD | mild | Macrothrombocytopenia | [43] | |
TUBB-1-related thrombocytopenia | AD | mild | Macrothrombocytopenia; platelet anisocytosis | [44] | |
SLFN14-related thrombocytopenia | AD | mild/moderate | Macrothrombocytopenia; δ-granule deficiency with decreased ATP secretion in response to ADP, collagen and TRAP-6 | [49] | |
Forms predisposing to additional diseases | ANKRD26-related thrombocytopenia | AD | mild/moderate | Reduced α-granules in some patients | [13] |
Congenital amegakaryocytic thrombocytopenia (CAMT) | AR | severe | Elevated serum levels of TPO | [22] | |
DIAPH1-related thrombocytopenia | AD | mild/severe | Macrothrombocytopenia | [31] | |
ETV6-related thrombocytopenia | AD | mild/moderate | Decreased ability of platelets to spread on fibrinogen covered surfaces; abnormal clot retraction | [14] | |
Familial platelet disorder with predisposition to hematological malignancies (FPD/AML) | AD | moderate | Abnormal aggregation in response to multiple agonists; δ (occasionally α)-granule deficiency | [25] | |
MYH9-related disease | AD | mild/severe | Macrothrombocytopenia; Döhl-like body cytoplasmic leukocyte inclusions | [38] | |
Thrombocytopenia associated with sitosterolemia | moderate/severe | Macrothrombocytopenia; hyperactivatable platelets with constitutive binding of fibrinogen to αIIbβ3 integrin; shedding of GPIbα; impaired platelet adhesion to von Willebrand factor | [46] |
This entry is adapted from the peer-reviewed paper 10.3390/jcm10030533